...
首页> 外文期刊>Alimentary pharmacology & therapeutics. >Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
【24h】

Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.

机译:一项回顾性队列研究显示,因50岁或50岁以上患者使用低剂量阿司匹林而导致胃肠道不良事件的住院治疗:一项回顾性队列研究。

获取原文
获取原文并翻译 | 示例

摘要

Background Use of aspirin with non-steroidal anti-inflammatory drugs increases the risk of gastrointestinal ulcers; however, it is not clear if this risk varies with the non-steroidal anti-inflammatory drug used. Aim To assess the risk of gastrointestinal hospitalizations attributable to aspirin in patients 50 years or older also using non-steroidal anti-inflammatory drugs. Methods Administrative data of patients 50 years or older who received a non-steroidal anti-inflammatory drug or acetaminophen prescription between 1998 and 2004 were used. Results Study patients received 7 412 992 non-steroidal anti-inflammatory drug prescriptions and 5 614 044 acetaminophen prescriptions among which 23% and 32%, respectively, were dispensed to aspirin users. Time-dependent Cox regression models revealed that, compared to patients using acetaminophen (without aspirin), the adjusted hazard ratio (95% CI) among non-users of aspirin were: rofecoxib 1.3 (1.2, 1.5), celecoxib 0.7 (0.6, 0.8), diclofenac 1.5 (1.2, 1.7), ibuprofen 0.9 (0.6, 1.4), naproxen 2.5 (2.1, 3.0) and piroxicam 1.5 (0.8, 2.8); among users of aspirin: rofecoxib 3.2 (2.8, 3.7), celecoxib 1.8 (1.5, 2.1), diclofenac 2.8 (2.2, 3.5), ibuprofen 1.4 (0.8, 2.7), naproxen 2.2 (1.6, 3.0) and piroxicam 2.0 (0.8, 5.4). The risk attributable to aspirin varied from none with naproxen to 61% (53%, 68%) with celecoxib. Conclusion The increase in gastrointestinal hospitalization attributable to aspirin differed with the non-steroidal anti-inflammatory drug used, and seemed higher with cyclo-oxygenase-2 inhibitors than with non-selective non-steroidal anti-inflammatory drugs.
机译:背景阿司匹林与非甾体类抗炎药一起使用会增加胃肠道溃疡的风险。然而,尚不清楚这种风险是否随所使用的非甾体类抗炎药而变化。目的评估使用阿糖类抗炎药的50岁或50岁以上患者因阿司匹林在胃肠道住院的风险。方法使用1998年至2004年期间接受非甾体类抗炎药或对乙酰氨基酚处方的50岁或50岁以上患者的行政资料。结果研究患者接受了7 412 992非类固醇抗炎药处方和5 614 044对乙酰氨基酚处方,其中分别向阿司匹林使用者分配了23%和32%。时间依赖性Cox回归模型显示,与使用对乙酰氨基酚(不使用阿司匹林)的患者相比,非阿司匹林使用者中调整后的危险比(95%CI)为:罗非昔布1.3(1.2,1.5),塞来昔布0.7(0.6,0.8) ),双氯芬酸1.5(1.2,1.7),布洛芬0.9(0.6,1.4),萘普生2.5(2.1,3.0)和吡罗昔康1.5(0.8,2.8);阿司匹林使用者:罗非昔布3.2(2.8,3.7),塞来昔布1.8(1.5,2.1),双氯芬酸2.8(2.2,3.5),布洛芬1.4(0.8,2.7),萘普生2.2(1.6,3.0)和吡罗昔康2.0(0.8, 5.4)。阿司匹林引起的风险范围从使用萘普生的无风险到使用塞来昔布的占61%(53%,68%)不等。结论阿司匹林引起的胃肠道住院治疗的增加与所使用的非甾体类抗炎药有所不同,并且环氧化酶2抑制剂似乎比非选择性非甾体类抗炎药高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号